BPC-157: what the animal literature shows, and what nobody has tested in people

Fifteen amino acids derived from a sequence found in human gastric juice, with one of the largest animal literatures of any research peptide and essentially no controlled human data. Both halves of that sentence matter.

What it is, and what the studies actually measured

BPC-157 is a synthetic peptide corresponding to a fifteen-residue fragment of a larger protein isolated from gastric juice. Animal-only or theoretical The published work is overwhelmingly in rodents, and within that literature the findings are consistent and broad: accelerated healing of transected tendon, ligament and muscle; protection of gastrointestinal mucosa against several kinds of injury; effects on blood-vessel formation; and a range of neurological findings. Proposed mechanisms centre on angiogenesis through the VEGF pathway, modulation of nitric oxide signalling, and upregulation of growth factor receptors in healing tissue.

The consistency of that literature is genuinely notable, and so is a second fact about it: a large share of it comes from a small number of related research groups. That is not an accusation, it is a description of the evidence base, and it is exactly the situation where independent replication carries more weight than volume. Consistent findings from one lineage of investigators are weaker evidence than the same findings from several.

What does not exist is a published randomised controlled trial in humans for any indication. Not a negative one — an absent one. Everything said about human dose, human response, human duration or human safety is extrapolation from animals and uncontrolled reports, and the confidence with which it is usually stated is not supported by anything.

Routes, stability and the oral question

Animal-only or theoretical The peptide is described as stable in gastric juice, which is unusual for a peptide and is the basis for oral administration — the argument being that it survives the stomach to act locally on gastrointestinal tissue. Local action on the gut is a coherent reading of that. Systemic absorption of an intact fifteen-residue peptide from the gut is a much stronger claim, and it is the one people make when they describe oral administration for a tendon injury.

Injected subcutaneously, the app models a half-life of about four hours and flags it as an estimate — meaning published human pharmacokinetic data is limited or absent and the figure is inferred. Every number derived from it, on this page or anywhere, inherits that. Treat the four hours as an order of magnitude rather than a measurement.

Administration near the site of an injury is the common practice and is described throughout the animal work, though several of the animal findings were produced with systemic administration. Whether local placement adds anything in humans is another question nobody has answered.

What "no serious adverse events reported" is worth

The app's entry notes an absence of serious adverse events in the literature, and that is accurate as far as it goes. It is worth being clear about how far that is. Adverse events are found by controlled trials designed to look for them and by surveillance systems that collect them; neither exists here. An absence of reports from a body of animal studies and uncontrolled human use is not evidence of safety, and the specific unknowns are the ones that a short study cannot reach: chronic administration, interaction with existing disease, and the theoretical concern that attaches to any compound promoting angiogenesis in a person who may have an undetected malignancy.

The sourcing problem compounds it. There is no approved product, so identity, purity and concentration depend entirely on whoever produced the vial. A peptide sold as BPC-157 may be a different sequence, a partially degraded one, or a different quantity than the label says, and none of that is visible. This site names no vendor and no testing service.

The reasonable position is that this is an interesting compound with a real mechanistic literature and an unusually large evidence gap between the animal work and the way it is used. Anyone using it or considering it should have that conversation with a clinician who knows their history, and anything that feels wrong while using it is a reason to stop and ask rather than to continue.

The curve, the accumulation ratio and the peak-to-trough figures have a page of their own: BPC-157 half-life and steady state.

The dosing rows the app records

Animal-only or theoretical Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for BPC-157, verbatim. None of the analytes it names has a page here yet.

Drawbacks and risks the app records

From the app's own entry, and unusually honest for a compound this popular — the first two items are the whole story.

• Limited human RCT data — primarily animal evidence
• Long-term safety not yet established
• Quality control varies by source
• Not FDA approved
• Mechanism not fully characterized in humans

Interaction rules that name BPC-157

From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.

Questions people actually ask

Is there any human trial evidence?

No published randomised controlled trial for any indication. There is animal work, there are uncontrolled human reports, and there is a large amount of confident writing that does not distinguish between those and a trial. That distinction is the most important thing to carry away from this page.

Oral or injected?

The peptide is reported stable in gastric juice, which supports local action on gastrointestinal tissue taken orally. Systemic absorption sufficient to act on a distant tendon is a much larger claim and is not established. The app records both routes in its dosing rows above; which, if either, is appropriate is not a question this page answers.

How does it compare with TB-500?

They are different peptides with different proposed mechanisms — BPC-157 is associated with angiogenesis and growth-factor signalling, TB-500 with actin regulation and cell migration — and both rest on animal data. They are frequently used together, which is a community practice rather than a tested combination. The blend calculator covers the arithmetic of a shared vial, not the case for one.

What does the estimated half-life flag mean?

That app.html marks the figure as inferred rather than measured, because published human pharmacokinetic data is limited or absent. Any duration, clearance or accumulation figure calculated from it carries the same uncertainty, and the half-life page says so on every number it prints.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.